

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/067,477	02/04/2002	Shuji Hinuma	70342/47147CPA-C	8361
21874 75	90 10/23/2003		EXAMI	INER
EDWARDS & ANGELL, LLP			ULM, JOHN D	
P.O. BOX 9169		ART UNIT	PAPER NUMBER	
BOSTON, MA 02209			ARTONII	TAFER NUMBER
			1646	

DATE MAILED: 10/23/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
7	10/067,477	HINUMA ET AL.			
Office Action Summary	Examiner	Art Unit			
· · · · · ·	John D. Ulm	1646			
The MAILING DATE of this communication a					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statt - Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b). Status	I. 1.136(a). In no event, however, may a neply within the statutory minimum of thirt by will apply and will expire SIX (6) MON ute, cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).			
1) Responsive to communication(s) filed on	***************************************				
2a) ☐ This action is FINAL . 2b) ☐ 3	This action is non-final.				
3) Since this application is in condition for allow					
closed in accordance with the practice under Disposition of Claims	er <i>Ex par</i> te <i>Quayl</i> e, 1935 C.L	J. 11, 453 O.G. 213.			
4) Claim(s) 1-15 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) <u>1-15</u> are subject to restriction and/o	r election requirement.				
Application Papers					
9) The specification is objected to by the Examir					
10) The drawing(s) filed on is/are: a) acc	•				
Applicant may not request that any objection to					
11) The proposed drawing correction filed on		sapproved by the Examiner.			
If approved, corrected drawings are required in a					
12) The oath or declaration is objected to by the E	Examiner.				
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for forei	gn priority under 35 U.S.C. §	§ 119(a)-(d) or (t).			
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority docume					
2. Certified copies of the priority docume					
 3. Copies of the certified copies of the principle application from the International E * See the attached detailed Office action for a list 	Bureau (PCT Rule 17.2(a)).				
14) Acknowledgment is made of a claim for domes	stic priority under 35 U.S.C.	§ 119(e) (to a provisional application).			
a) The translation of the foreign language p					
Attachment(s)	one priority under do 0,0.0.	33 120 GHQ/01 121.			
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of I	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)			

- 1) Claims 1 to 15 are pending in the instant application.
- 2) Restriction to one of the following inventions is required under 35 U.S.C. 121:
- I. Claims 1 to 4 and 11 to 13, drawn to a G protein-coupled receptor, a kit containing that receptor and a method of use, classified in class 436, subclass 501 and class 530, subclass 350.
- II. Claims 5 to 10, drawn to a nucleic acid encoding a G protein-coupled receptor, a vector and host cell containing that nucleic acid, and a method of use, classified in class 435, subclass 69.1 and class 536, subclass 23.5.
- III. Claim 14, drawn to a compound of undefined constitution, classified in class undeterminable, subclass undeterminable.
- IV. Claim 15, drawn to an antibody, classified in class 530, subclass 388.22.

The inventions are distinct, each from the other because:

The receptor protein that is invention I, the nucleic acid that is invention II, the compound that is invention III and the antibody that is invention IV are four different chemical compounds each of which can be made and used without the other and, if found patentable, would support a separate patent. Distinctness is further shown by the fact that these different chemical compounds lack a common utility which is based upon a common special technical feature which is disclosed as being responsible for that common utility. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects. (MPEP § 806.04, MPEP § 808.01).

Art Unit: 1646

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

Applicant is advised that a number of the pending claims are improperly dependant claims. A properly dependant claim shall not conceivably be infringed without infringing the claim from which it depends. The nucleic acid of claim 5, for example, can readily be infringed without infringing the protein of claim 1 from which it depends. Further, 35 U.S.C. § 112, fifth paragraph, states that a multiple dependant claim can not depend from another multiple dependant claim and must refer to the claims from which it depends in the alternative only. Claims 9, 10 and 14 of the instant application, for example, are improperly multiple dependant claims. Applicant may wish to amend the claims in response to this communication to avoid these issues in the next action.

Art Unit: 1646

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242 or (703) 872-9306. Official responses under 37 C.F.R. § 1.116 should be directed to (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JOHN ULM PRIMARY EXAMINER GROUP 1600